Allogene Therapeutics (ALLO)
(Real Time Quote from BATS)
$2.86 USD
-0.18 (-5.92%)
Updated Apr 25, 2024 11:04 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Allogene Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 38 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 38 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 328 | 336 | 294 | 258 | 202 |
Income After Depreciation & Amortization | -328 | -335 | -256 | -258 | -202 |
Non-Operating Income | 0 | 3 | -1 | 8 | 17 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -327 | -333 | -257 | -250 | -185 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -327 | -333 | -257 | -250 | -185 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -327 | -333 | -257 | -250 | -185 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -320 | -318 | -238 | -247 | -201 |
Depreciation & Amortization (Cash Flow) | 7 | 17 | 17 | 11 | 1 |
Income After Depreciation & Amortization | -328 | -335 | -256 | -258 | -202 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 156.93 | 143.15 | 135.82 | 120.37 | 101.06 |
Diluted EPS Before Non-Recurring Items | -2.01 | -2.32 | -1.89 | -2.08 | -1.83 |
Diluted Net EPS (GAAP) | -2.09 | -2.32 | -1.89 | -2.08 | -1.83 |
Fiscal Year end for Allogene Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | -0.04 | 0.04 | 0.04 | 0.05 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | -0.04 | 0.04 | 0.04 | 0.05 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 71.88 | 63.02 | 80.56 | 99.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -71.92 | -62.98 | -80.52 | -99.07 |
Non-Operating Income | NA | -4.08 | 1.66 | 2.53 | 0.37 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -89.26 | -61.32 | -77.99 | -98.70 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -89.26 | -61.32 | -77.99 | -98.70 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -89.26 | -61.32 | -77.99 | -98.70 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 168.34 | 167.65 | 146.80 | 144.56 |
Diluted EPS Before Non-Recurring Items | NA | -0.43 | -0.37 | -0.53 | -0.68 |
Diluted Net EPS (GAAP) | NA | -0.51 | -0.37 | -0.53 | -0.68 |